睿知中国医院研究地图
候选清单

正在招募胃肠道间质瘤II/III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

ClinicalTrials.gov 上登记的一项胃肠道间质瘤开放试验。牵头方不是本站收录的医院;本站收录的 31 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 31

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心贵州医科大学附属医院Affiliated Hospital of Guizhou Medical University贵阳医院页面
  2. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  3. 研究中心哈尔滨医科大学第三临床医学院Cancer Hospital, Harbin Medical University哈尔滨医院页面
  4. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  5. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  6. 研究中心福建医科大学附属第一医院First Affiliated Hospital of Fujian Medical University福州医院页面
  7. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  8. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  9. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  10. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  11. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  12. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  13. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  14. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  15. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  16. 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
  17. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  18. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  19. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  20. 研究中心上海交通大学医学院附属仁济医院Renji Hospital上海医院页面
  21. 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
  22. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  23. 研究中心山东省立医院Shandong Provincial Hospital济南医院页面
  24. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  25. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  26. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  27. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  28. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  29. 研究中心四川大学华西医院West China Hospital成都医院页面
  30. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  31. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07379047,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Participants who have histologically confirmed locally advanced, unresectable, or metastatic GIST.

    入选标准第 3 条

    Participants with confirmed KIT gene mutation based on local or central laboratory molecular pathology reports. Mutation status must be determined using tissue-based PCR or DNA sequencing methods. The report should include results on the presence or absence of KIT exon 9/11/17 mutations for randomization stratification in Part 1 and efficacy-related analyses throughout the study. The molecular pathology report indicating KIT mutation status shall be submitted to the medical monitor for review during the screening period. If a local molecular pathology report is unavailable or provides insufficient information, archived tumor tissue samples or fresh biopsy samples must be provided for central laboratory confirmation of mutation status prior to enrollment.

    入选标准第 6 条

    Tumor sample requirement: Archival tumor samples in the form of formalin-fixed paraffin-embedded (FFPE) tissue sections or FFPE blocks obtained prior to enrollment, or tissue samples from a tumor biopsy (excisional, core needle, or fine-needle aspiration).

    入选标准第 9 条

  3. Part 1: Patients who have failed prior treatment with imatinib (including adjuvant therapy) and sunitinib for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.

    入选标准第 4 条

    Part 2: Patients who have failed prior treatment with imatinib (including adjuvant therapy) for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.

    入选标准第 5 条

    Male participants: Male participants must agree to use contraception as detailed in Appendix 9 during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period.

    入选标准第 19 条

    Part 1: Participants who have received prior treatment with NB003 or regorafenib. Part 2: Participants who have received prior treatment with NB003 or sunitinib.

    排除标准第 1 条

    Participants who have received any systemic anti-tumor therapy within 7 days prior to enrollment.

    排除标准第 2 条

    Participants who have received radiation therapy to >30% of the bone marrow or extensive radiation therapy within 4 weeks prior to enrollment.

    排除标准第 4 条

    Any unresolved prior treatment toxicity greater than CTCAE Grade 1 at the start of study treatment, with the exception of alopecia, hemoglobin (see Inclusion Criterion #10), Grade 2 hypothyroidism stable on hormone replacement therapy, and Grade 2 pre-existing treatment-related neuropathy.

    排除标准第 12 条

    Participants currently using (or unable to discontinue at least 2 weeks prior to enrollment) drugs or herbal supplements known to be strong inhibitors or inducers of CYP3A4, and other prohibited concomitant medications (Appendix 3).

    排除标准第 23 条

  4. Participants with an ECOG PS of 0 to 1.

    入选标准第 8 条

  5. Hemoglobin >=9 g/dL (5.59 mmol/L).

    入选标准第 12 条

    Absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3).

    入选标准第 13 条

    Platelet count >=100 x 10\^9/L (100,000/mm\^3).

    入选标准第 14 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x upper limit of normal (ULN) (for participants without liver metastases); AST and ALT <= 5 x ULN (for participants with liver metastases).

    入选标准第 15 条

    Creatinine clearance >=60 mL/min as calculated by the Cockcroft-Gault formula or 24-hour urine collection.

    入选标准第 17 条

    International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) <=1.5 x ULN; however, if a participant is receiving anticoagulant therapy, PT or aPTT within the therapeutic range of the anticoagulant is acceptable.

    入选标准第 18 条

  6. Active infection, including active hepatitis B [defined as detectable HBV-DNA by local laboratory. Participants who are HBsAg positive or HBcAb positive at screening should have HBV-DNA tested] and active hepatitis C [defined as detectable HCV-RNA by local laboratory. Participants who are HCV antibody positive at screening should have HCV-RNA tested].

    排除标准第 5 条

    Participants who have experienced a National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 Grade 3 or higher bleeding event within 4 weeks prior to enrollment.

    排除标准第 13 条

    History of other primary neoplasm malignant diagnosed or requiring treatment within 3 years prior to enrollment. The following prior malignancies are not exclusion criteria: completely resected basal cell and squamous cell skin cancers, cured localized prostate cancer, cured superficial or non-muscle invasive bladder cancer, and completely resected carcinoma in situ of any site.

    排除标准第 25 条

  7. Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    入选标准第 20 条

    WOCBP must have a negative serum pregnancy test result during screening within 14 days prior to enrollment.

    入选标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07379047,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Participants are >=18 years of age (or the legal adult age as per local regulations, whichever is older) at the time of signing the ICF.
  2. Participants, or legally authorized representatives permitted by local regulations, provide written informed consent for participation in the study.
  3. Participants who have histologically confirmed locally advanced, unresectable, or metastatic GIST.
  4. Part 1: Patients who have failed prior treatment with imatinib (including adjuvant therapy) and sunitinib for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.
  5. Part 2: Patients who have failed prior treatment with imatinib (including adjuvant therapy) for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.
  6. Participants with confirmed KIT gene mutation based on local or central laboratory molecular pathology reports. Mutation status must be determined using tissue-based PCR or DNA sequencing methods. The report should include results on the presence or absence of KIT exon 9/11/17 mutations for randomization stratification in Part 1 and efficacy-related analyses throughout the study. The molecular pathology report indicating KIT mutation status shall be submitted to the medical monitor for review during the screening period. If a local molecular pathology report is unavailable or provides insufficient information, archived tumor tissue samples or fresh biopsy samples must be provided for central laboratory confirmation of mutation status prior to enrollment.
  7. Participants with at least one measurable lesion according to mRECIST.
  8. Participants with an ECOG PS of 0 to 1.
  9. Tumor sample requirement: Archival tumor samples in the form of formalin-fixed paraffin-embedded (FFPE) tissue sections or FFPE blocks obtained prior to enrollment, or tissue samples from a tumor biopsy (excisional, core needle, or fine-needle aspiration).
  10. Participants with an expected life expectancy of >=12 weeks.
  11. Participants shall have adequate organ and bone marrow function. Transfusions and/or treatment with erythropoietin and/or granulocyte colony stimulating factor/granulocyte macrophage colony stimulating factor (G-CSF/GM-CSF) are not permitted within 14 days prior to the screening laboratory blood draw under any circumstances. The criteria are defined as follows:
  12. Hemoglobin >=9 g/dL (5.59 mmol/L).
  13. Absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3).
  14. Platelet count >=100 x 10\^9/L (100,000/mm\^3).
  15. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x upper limit of normal (ULN) (for participants without liver metastases); AST and ALT <= 5 x ULN (for participants with liver metastases).
  16. Total bilirubin <=1.5 x ULN. Participants with a confirmed diagnosis of Gilbert's syndrome (persistent or recurrent unconjugated hyperbilirubinemia in the absence of hemolysis or hepatic pathology) may be enrolled if total bilirubin <=3 x ULN.
  17. Creatinine clearance >=60 mL/min as calculated by the Cockcroft-Gault formula or 24-hour urine collection.
  18. International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) <=1.5 x ULN; however, if a participant is receiving anticoagulant therapy, PT or aPTT within the therapeutic range of the anticoagulant is acceptable.
  19. Male participants: Male participants must agree to use contraception as detailed in Appendix 9 during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period.
  20. Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  21. WOCBP must have a negative serum pregnancy test result during screening within 14 days prior to enrollment.

排除标准:Exclusion Criteria:

  1. Part 1: Participants who have received prior treatment with NB003 or regorafenib. Part 2: Participants who have received prior treatment with NB003 or sunitinib.
  2. Participants who have received any systemic anti-tumor therapy within 7 days prior to enrollment.
  3. Participants who have undergone major surgery (excluding vascular access placement, tumor biopsy, and feeding tube placement) or major palliative interventions (such as transarterial chemoembolization) within 4 weeks prior to enrollment.
  4. Participants who have received radiation therapy to >30% of the bone marrow or extensive radiation therapy within 4 weeks prior to enrollment.
  5. Active infection, including active hepatitis B [defined as detectable HBV-DNA by local laboratory. Participants who are HBsAg positive or HBcAb positive at screening should have HBV-DNA tested] and active hepatitis C [defined as detectable HCV-RNA by local laboratory. Participants who are HCV antibody positive at screening should have HCV-RNA tested].
  6. Any of the following cardiac-related criteria:
  7. Uncontrolled persistent (>4 weeks) hypertension (>140/90 mmHg).
  8. New York Heart Association (NYHA) Class (Appendix 11) III and IV heart disease, active ischemia, or other uncontrolled cardiac conditions such as angina.
  9. QTc interval Corrected QT interval using Fridericia's formula (QTcF) >=470 ms (based on 3 ECG results) or history of long QT syndrome.
  10. Resting ECG showing any clinically significant abnormalities in rhythm, conduction, or morphology (e.g., complete left bundle branch block, atrioventricular block third degree, atrioventricular block second degree, PR interval >250 ms).
  11. Left ventricular ejection fraction (LVEF) <50%.
  12. Any unresolved prior treatment toxicity greater than CTCAE Grade 1 at the start of study treatment, with the exception of alopecia, hemoglobin (see Inclusion Criterion #10), Grade 2 hypothyroidism stable on hormone replacement therapy, and Grade 2 pre-existing treatment-related neuropathy.
  13. Participants who have experienced a National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 Grade 3 or higher bleeding event within 4 weeks prior to enrollment.
  14. Participants who have experienced an arterial thrombotic or embolic event (e.g., cerebrovascular accident, including transient ischemic attack) within 6 months prior to enrollment, or a venous thrombotic event (including pulmonary embolism or deep vein thrombosis) within 3 months prior to enrollment.
  15. Participants who have experienced a seizure for any reason within 6 months prior to enrollment.
  16. Participants with known bleeding disorders or risk of intracranial hemorrhage (e.g., unexcised or unrepaired cerebral aneurysm, cerebrovascular malformation), or history of intracranial hemorrhage within 1 year prior to randomization.
  17. Participants with unhealed wounds, active ulceration, gastrointestinal perforation, or fracture within 3 months prior to enrollment.
  18. Participants with brain metastases.
  19. History of pancreatitis with prior tyrosine kinase inhibitors use, or current evidence of mild to moderate pancreatitis.
  20. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulation, or significant bowel resection that may affect adequate absorption of NB003 and regorafenib.
  21. Any other clinically significant comorbidity, such as uncontrolled lung disorder, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other condition that, in the investigator's judgment, may affect protocol compliance, interfere with interpretation of study results, or increase participant safety risk.
  22. Participants judged by the investigator to be unwilling or unable (including incompetence) to comply with study procedures, restrictions, and requirements.
  23. Participants currently using (or unable to discontinue at least 2 weeks prior to enrollment) drugs or herbal supplements known to be strong inhibitors or inducers of CYP3A4, and other prohibited concomitant medications (Appendix 3).
  24. History of hypersensitivity to the active or inactive ingredients of NB003, regorafenib, or drugs with similar chemical structure or class to NB003 or regorafenib.
  25. History of other primary neoplasm malignant diagnosed or requiring treatment within 3 years prior to enrollment. The following prior malignancies are not exclusion criteria: completely resected basal cell and squamous cell skin cancers, cured localized prostate cancer, cured superficial or non-muscle invasive bladder cancer, and completely resected carcinoma in situ of any site.

引自 ClinicalTrials.gov, NCT07379047, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07379047,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07379047